Related Experiment Video

Updated: May 14, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells

Shudong Zhu1, Matthew B Cohen, Jeffrey D Bjorge

  • 1Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. stoneoscar@gmail.com

Journal of Cellular and Molecular Medicine
|February 8, 2013
PubMed

Insights

Combining PI3-K/Akt inhibitors with BH3-mimetics shows promise for advanced renal cell carcinoma (RCC). This strategy enhances cell death by targeting key proteins, suggesting a new therapeutic approach for RCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Phosphoinositide 3-kinase/Akt (PI3-K/Akt) inhibitors are under clinical investigation for advanced renal cell carcinoma (RCC).
  • Enhancing the efficacy of PI3-K/Akt inhibitors is crucial for improving patient outcomes.
  • PI3-K inhibition is anticipated to induce pro-apoptotic effects, suggesting potential synergy with BH3-mimetics.

Purpose of the Study:

  • To investigate the synergistic potential of combining a PI3-K inhibitor (LY294002) with a BH3-mimetic (ABT-737) in RCC cell lines.
  • To elucidate the molecular mechanisms underlying the combined therapeutic effect.

Main Methods:

  • Treatment of RCC cell lines with LY294002 and ABT-737, individually and in combination.
  • Assessment of apoptosis markers, including Poly (ADP-ribose) polymerase (PARP) cleavage.
  • Analysis of apoptosis-related protein expression levels (Mcl-1, XIAP, Bim) and caspase activation (caspase 3, caspase 8).

Main Results:

  • Combined treatment significantly increased PARP cleavage and cell death across all tested RCC cell lines.
  • Synergistic cell death correlated with reduced Mcl-1 and XIAP levels, and increased Bim levels.
  • The enhanced lethality was dependent on caspase 3 and 8 activation and the regulation of Mcl-1, XIAP, and Bim.

Conclusions:

  • The combination of PI3-K inhibitors and BH3-mimetics demonstrates significant synergistic anti-cancer activity in RCC.
  • This combinatorial approach, targeting apoptosis pathways, represents a potentially viable therapeutic strategy for advanced RCC.

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...